A Fibrinogen‐Mimicking, Activated‐Platelet‐Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy. Issue 19 (31st July 2022)

• Record Type: Journal Article
• Authors: Huang, Yu; Jiang, Jingxuan; Ren, Jie; Guo, Yuanyuan; Zhao, Qianqian; Zhou, Jia; Li, Yuehua; Chen, Rongjun
• Is Part Of: Advanced healthcare materials. Volume 11:Issue 19(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-31
• Subjects: chitosan -- fibrinogen‐mimicking nanocoacervate -- targeted thrombolysis -- thrombus penetration -- tissue plasminogen activators; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202201265
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: The development of a fibrinolytic system with long circulation time, high thrombus targeting, efficient thrombus penetration, effective thrombolysis, and minimal hemorrhagic risk remains a major challenge. Herein, inspired by fibrinogen binding to activated platelets in thrombosis, this article reports a fibrinogen‐mimicking, activated‐platelet‐sensitive nanocoacervate to enhance thrombus penetration of tissue plasminogen activator (tPA) for targeted thrombolytic therapy. This biomimetic nanothrombolytic system, denoted as RGD‐Chi@tPA, is constructed by "one‐pot" coacervation through electrostatic interactions between positively charged arginine‐glycine‐aspartic acid (RGD)‐grafted chitosan (RGD‐Chi) and negatively charged tPA. Flow cytometry and confocal laser scanning microscopy measurements show targeting of RGD‐Chi@tPA to activated platelets. Controlled tPA release triggered by activated platelets at a thrombus site is demonstrated. Its targeted fibrinolytic and thrombolytic activities are measured in in vitro models. The pharmacokinetic profiles show that RGD‐Chi@tPA can significantly prolong circulation time compared to free tPA. In a mouse tail thrombus model, RGD‐Chi@tPA displays efficient thrombus targeting and penetration, enabling a complete vascular recanalization as confirmed by the fluorescence imaging, histochemical assay, and laser speckle contrast imager. Consequently, RGD‐Chi@tPA induces a substantial enhancement in thrombolysis with minimal hemorrhagic risk compared to free tPA. This simple, effective, and safe platform holds great promise for the development of thrombolytic nanomedicines. Abstract : Inspired by fibrinogen binding to activated platelets in thrombosis, a fibrinogen‐mimicking, activated‐platelet‐sensitive nanocoacervate (RGD‐Chi@tPA) is developed by "one‐pot" coacervation through simple electrostatic interaction between positively charged arginine‐glycine‐aspartic acid‐grafted chitosan and negatively charged tissue plasminogen activator to enhance thrombus targeting and penetration for effective thrombolytic therapy.